Clinical Significance of Platelet Closure Time in Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2020.04.026
- Author:
Ya-Nan TANG
1
;
Hu-Jun LI
1
;
Ya-Qi WU
1
;
Ting XU
1
;
Meng-Jun GE
1
;
Kai-Lin XU
1
;
Zheng-Yu LI
2
Author Information
1. Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China,E-mail：Lizhenyumd@163.com.
- Publication Type:Journal Article
- MeSH:
Blood Platelets;
Bone Marrow;
Bortezomib;
Humans;
Multiple Myeloma;
Platelet Count
- From:
Journal of Experimental Hematology
2020;28(4):1240-1244
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical significance of platelet closure time (PCT) in patients with multiple myeloma (MM).
METHODS:Peripheral blood samples of 50 newly diagnosed MM patients treated in our hospital from July 2018 to November 2019 and 34 healthy persons underuent physical at the same time were collected. PCT induced by collagen/epinephrine (CEPI) and collagen/adenosinediphosphate (CADP) in peripheral blood were detected by PFA-200，and the clinical data included age, sex, leukocyte count, hemoglobin level, platelet count and level of serum creatinine, cystatin c, blood calcium, β-microglobulin (β-MG), bone marrow plasma cells, light chain protein, as well as the MM types, ISS stage of patients were collected.
RESULTS:The level of PCT in MM patients was significantly higher than that in healthy persons; the level of PCT were significantly increased with the increasing of ISS stage in newly diagnosed MM patients; After chemotherapy with bortezomib/dexamethasone (BD), the level of PCT in 15 patients who were responded to the treatment was significantly lower than those before treatment.
CONCLUSION:The platelet closure time is abnormal in MM patients, moreover, relates to the progress of the disease. It has an important clinical significance for the evaluation of diagnostic stage and therapeutic efficacy evaluation of MM patients.
